A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

Description

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the current standard test, CA125, in identifying cancer. This study aims to evaluate the effectiveness of the Cleo Diagnostics (CleoDX) Ovarian Adnexal Mass Score Test System. This test measures five analytes in the blood and provides a score indicating the likelihood of cancer in patients with an adnexal mass requiring surgery. The test is designed to assist doctors in making better-informed decisions about surgery and patient care by providing a more accurate pre-surgical assessment of cancer risk. By doing so, it aims to improve patient outcomes and ensure that those with malignant conditions receive the appropriate specialist care.

Conditions

Ovarian Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the current standard test, CA125, in identifying cancer. This study aims to evaluate the effectiveness of the Cleo Diagnostics (CleoDX) Ovarian Adnexal Mass Score Test System. This test measures five analytes in the blood and provides a score indicating the likelihood of cancer in patients with an adnexal mass requiring surgery. The test is designed to assist doctors in making better-informed decisions about surgery and patient care by providing a more accurate pre-surgical assessment of cancer risk. By doing so, it aims to improve patient outcomes and ensure that those with malignant conditions receive the appropriate specialist care.

Validation of Ovarian Adnexal Mass Assessment Score Test System

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

Condition
Ovarian Neoplasms
Intervention / Treatment

-

Contacts and Locations

Chandler

New Horizons Clinical Trials, Chandler, Arizona, United States, 85224

Las Vegas

Women's Cancer Center of Nevada, Las Vegas, Nevada, United States, 89106

Fresh Meadows

ES Clinical Research Group LLC, Fresh Meadows, New York, United States, 11365

Lewisville

Prime Clinical Research - Lewisville, Lewisville, Texas, United States, 75067

Mesquite

Vast Clinical Research-Holy Cross, Mesquite, Texas, United States, 75149

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * female patients =\> 18 years of age at the time of consent
  • * Can provide written informed consent
  • * Have an ovarian cyst or adnexal mass (simple, complex, or solid ovarian/pelvic mass) identified through imaging examination (e.g. transvaginal ultrasound - TVU) that requires surgery, but have not yet undergone this surgery
  • * Any prior confirmed diagnosis of, or treatment for, ovarian cancer
  • * Any prior surgery resulting in removal of both ovaries
  • * Prior history of gynecological malignancy (within last 2 years)
  • * Prior history of melanoma (within last 2 years)
  • * Prior treatment (within 12 months of sample collection) with chemotherapy, radiotherapy or immunotherapy
  • * Immune-compromised. Definition: those whose weakened immune system may render them more susceptible to infection, illness, or complications. These may include patients with immune-suppressive conditions (e.g. HIV/AIDS), patients undergoing immuno-, chemo- or radio-therapy (within the last 12 months) for any reason, receiving immune suppressive therapies (e.g. transplant recipients, individuals with known autoimmune disease), or with a primary immunodeficiency disorder (e.g. Lupus).
  • * Pregnant currently or within the last 3 months based on participant self-report

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cleo Diagnostics Ltd,

Chief Scientific Officer, STUDY_DIRECTOR, Cleo Diagnostics Ltd

Study Record Dates

2026-08